{
    "2018-10-15": [
        [
            {
                "time": "",
                "original_text": "[看好评级]医药生物行业2018年三季报业绩前瞻：医药需求刚性 预计增长保持稳健",
                "features": {
                    "keywords": [
                        "医药生物",
                        "三季报",
                        "业绩前瞻",
                        "需求刚性",
                        "增长稳健"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2018-10-12",
                "original_text": "【申万宏源医药闫天一团队】20181012周观点：医药需求刚性，预计增长保持稳健——医药生物行业2018年三季报业绩前瞻",
                "features": {
                    "keywords": [
                        "申万宏源",
                        "医药需求",
                        "刚性",
                        "增长稳健",
                        "三季报"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "[同步大市-B评级]医药行业周报：17种抗癌药新晋医保 鼓励创新仍是大方向",
                "features": {
                    "keywords": [
                        "抗癌药",
                        "医保",
                        "鼓励创新",
                        "医药行业"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "[买入评级]药明康德(603259)深度研究：最强创新航母 驰骋新药服务蓝海",
                "features": {
                    "keywords": [
                        "药明康德",
                        "创新航母",
                        "新药服务",
                        "蓝海"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}